Skip to main content
CDC Website

Search Results

Results 41 - 50 of 111

Integrated Preclinical / Clinical AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not Allowed)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point...

Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The scientific objective of this Funding Opportunity Announcement is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune...

Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The scientific objective of this Notice of Funding Opportunity is to encourage research to delineate the role of inflammasomes in the neuropathology produced by acute or chronic drug exposure and HIV infection. Understanding the involvement of inflammasomes in virus and drug-induced immune...

Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)

Application Due Date:
Funding Organization:
US Department of Health and Human Services National Institutes of Health

The purpose of this FOA is to provide a method for investigators to request gap filling preclinical services to academic and private institutions to assist with product development efforts and facilitate the advancement of promising therapeutics for HIV and HIV-associated co-infections (Hepatitis B...

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and...

Next Generation Multipurpose Prevention Technologies

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The objective of this Funding Opportunity Announcement (FOA) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and...

Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

Application Due Date:
Funding Organization:
US Department of Health and Human Services National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact...

Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

The purpose of this notice of funding opportunity (NOFO) is to develop technologies to improve the delivery of pharmacological, gene editing, or other cargoes for HIV and substance use disorder (SUD) mechanistic or therapeutic research.

This NOFO requires a Plan for Enhancing Diverse Perspectives...

Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)

Application Due Date:
Funding Organization:
The US Department of Health and Human Services National Institutes of Health

Human immunodeficiency virus (HIV) infection is widely prevalent in individuals in the reproductive age group. Globally, an estimated 1.3 million people living with HIV (PWH) become pregnant each year (UNAIDS data, 2019). With the advent of antiretroviral therapy (ART), significant progress has been...